Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF) lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ UCB, a global biopharmaceutical company, today announced new long-term data from the BIMZELX® (bimekizumab) Phase 2b study BE AGILE and its.
Belgian Biotech Firm UCB Gets US FDA Approval for Psoriasis Drug in Boost for Sales bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Bimekizumab is a novel, humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-7A and IL-17F, which are key cytokines driving inflammatory processes in plaque psoriasis.
FDA approves UCB's inflammatory disease drug Bimzelx for plaque psoriasis pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.